Cipla Limited has announced that it has entered into definitive agreements to acquire 100 percent stake in Inzpera Healthsciences Limited, a company focused on paediatric pharmaceutical and wellness products. Once the deal is completed, Inzpera will become a wholly owned subsidiary of Cipla. The company said in its regulatory filing that the move is in line with its long-term strategy to strengthen its presence in the paediatric and wellness segment, a fast-growing area within the Indian healthcare market.
The acquisition, valued at an enterprise value of around ₹120 crore, will be completed for a purchase consideration of approximately ₹110.65 crore after necessary working capital adjustments. Cipla clarified that the transaction will be an all-cash deal, and the final amount may vary depending on closing date adjustments. The acquisition is expected to be completed within a month from the signing of the transaction documents, subject to mutually agreed timelines between both parties.
Inzpera Healthsciences, founded in 2016, develops, manufactures and markets a range of differentiated paediatric pharmaceutical and wellness products. The company has been steadily expanding its operations and has reported consistent revenue growth over the past three years, with turnover of ₹26.75 crore in FY 2024-25, ₹22.05 crore in FY 2023-24, and ₹20.76 crore in FY 2022-23.
Cipla said the acquisition is a strategic move aimed at integrating Inzpera’s innovative paediatric portfolio with its own extensive distribution network and operational expertise. The company believes this combination will enhance scalability, drive growth, and enable it to reach a larger base of healthcare consumers across India.
